checkAd

     189  0 Kommentare Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer - Seite 3

    Aktuelle Themen


    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial and Registration Plan for Namodenoson in the Treatment of Liver Cancer - Seite 3 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has successfully concluded a meeting …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer